Location History:
- Umea, SE (2011 - 2012)
- Umeå, SE (2013)
Company Filing History:
Years Active: 2011-2013
Title: Innovations in CNS Disorder Treatments by Inventor Per Lundgren
Introduction
Per Lundgren is a notable inventor based in Umeå, Sweden, recognized for his contributions to the treatment of central nervous system (CNS) disorders. With a total of four patents to his name, Lundgren has been instrumental in advancing pharmaceutical research in this critical area of healthcare.
Latest Patents
Lundgren’s latest patents showcase his innovative approach to treating CNS disorders. One significant patent involves GABA-steroid antagonists and their use for the treatment of CNS disorders. This innovation includes compounds that exhibit 3alpha-hydroxy-5alpha/beta-steroid blocking action with minimal antagonism against the gamma-aminobutyric acid (GABA-A) receptor. This breakthrough suggests various methods for the prevention, treatment, and alleviation of CNS disorders, along with pharmaceutical compositions tailored for such purposes.
Another important patent by Lundgren focuses on pregnane steroids and their therapeutic applications for CNS disorders. These steroid compounds, possessing a hydrogen donor in the 3beta position, serve as effective blockers of the 3alpha-hydroxy-pregnan-steroid action. This invention demonstrates utility in preventing and treating steroid-related CNS disorders, with treatment methods based on the administration of these substances proposed for the development of pharmaceuticals addressing specific steroid-induced CNS issues.
Career Highlights
Per Lundgren has developed a rich career centered on pharmaceutical innovation and research, particularly in the realm of CNS disorders. His work has allowed him to carve out a niche in creating effective treatment methodologies and therapeutics that can significantly improve patients' quality of life. His commitment to scientific advancement is evident in his portfolio of patents and ongoing research.
Collaborations
Lundgren is known to collaborate with talented colleagues in his field, including Ming-De Wang and Torbjorn Backstrom. These partnerships enrich his research endeavors and enhance the quality of innovations emerging from Umecrine AB, the company where he works. Through collaborative efforts, he continues to push the boundaries of what is possible in CNS research.
Conclusion
In summary, Per Lundgren stands out as an influential inventor in the pharmaceutical field, particularly concerning the treatment of CNS disorders. His recent patents highlight significant advancements that can pave the way for innovative therapeutic solutions. With ongoing collaborations and a dedication to research, Lundgren's contributions will continue to resonate within the medical community and beyond.